Literature DB >> 20404117

Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.

Craig M Hill1, Kevin M Krause, Stacey R Lewis, Johanne Blais, Bret M Benton, Mathai Mammen, Patrick P Humphrey, Alfred Kinana, James W Janc.   

Abstract

Telavancin is a bactericidal, semisynthetic lipoglycopeptide indicated in the United States for the treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria and is under investigation as a once-daily treatment for nosocomial pneumonia. The related vanA and vanB gene clusters mediate acquired resistance to glycopeptides in enterococci by remodeling the dipeptide termini of peptidoglycan precursors from D-alanyl-D-alanine (D-Ala-D-Ala) to D-alanyl-D-lactate (D-Ala-D-Lac). In this study, we assessed the ability of telavancin to induce the expression of van genes in VanA- and VanB-type strains of vancomycin-resistant enterococci. Vancomycin, teicoplanin, and telavancin efficiently induced VanX activity in VanA-type strains, while VanX activity in VanB-type isolates was inducible by vancomycin but not by teicoplanin or telavancin. In VanA-type strains treated with vancomycin or telavancin, high levels of D-Ala-D-Lac-containing pentadepsipeptide were measured, while D-Ala-D-Ala pentapeptide was present at very low levels or not detected at all. In VanB-type strains, vancomycin but not telavancin induced high levels of pentadepsipeptide, while pentapeptide was not detected. Although vancomycin, teicoplanin, and telavancin induced similar levels of VanX activity in VanA-type strains, these organisms were more sensitive to telavancin, which displayed MIC values that were 32- and 128-fold lower than those of vancomycin and teicoplanin, respectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20404117      PMCID: PMC2897282          DOI: 10.1128/AAC.01737-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  The structure and mode of action of glycopeptide antibiotics of the vancomycin group.

Authors:  J C Barna; D H Williams
Journal:  Annu Rev Microbiol       Date:  1984       Impact factor: 15.500

2.  The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

Authors:  M Arthur; C Molinas; P Courvalin
Journal:  J Bacteriol       Date:  1992-04       Impact factor: 3.490

3.  Transposable multiple antibiotic resistance in Streptococcus pneumoniae.

Authors:  P Courvalin; C Carlier
Journal:  Mol Gen Genet       Date:  1986-11

4.  Phosphonamidate and phosphothioate dipeptides as potential inhibitors of VanX.

Authors:  K W Yang; J J Brandt; L L Chatwood; M W Crowder
Journal:  Bioorg Med Chem Lett       Date:  2000-05-15       Impact factor: 2.823

5.  The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci.

Authors:  R Quintiliani; S Evers; P Courvalin
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

6.  Modified peptidoglycan precursors produced by glycopeptide-resistant enterococci.

Authors:  J Messer; P E Reynolds
Journal:  FEMS Microbiol Lett       Date:  1992-07-01       Impact factor: 2.742

7.  Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.

Authors:  T D Bugg; G D Wright; S Dutka-Malen; M Arthur; P Courvalin; C T Walsh
Journal:  Biochemistry       Date:  1991-10-29       Impact factor: 3.162

8.  Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine.

Authors:  P E Reynolds; F Depardieu; S Dutka-Malen; M Arthur; P Courvalin
Journal:  Mol Microbiol       Date:  1994-09       Impact factor: 3.501

9.  Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

Authors:  M Arthur; C Molinas; F Depardieu; P Courvalin
Journal:  J Bacteriol       Date:  1993-01       Impact factor: 3.490

10.  New chromogenic dipeptide substrate for continuous assay of the D-alanyl-D-alanine dipeptidase VanX required for high-level vancomycin resistance.

Authors:  M Anissimova; L Yaouancq; F Noor; M-A Badet-Denisot; B Badet
Journal:  J Pept Res       Date:  2003-08
View more
  11 in total

Review 1.  Messenger functions of the bacterial cell wall-derived muropeptides.

Authors:  Marc A Boudreau; Jed F Fisher; Shahriar Mobashery
Journal:  Biochemistry       Date:  2012-03-27       Impact factor: 3.162

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  The activity of glycopeptide antibiotics against resistant bacteria correlates with their ability to induce the resistance system.

Authors:  Min Jung Kwun; Hee-Jeon Hong
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 4.  Acquired inducible antimicrobial resistance in Gram-positive bacteria.

Authors:  Scott T Chancey; Dorothea Zähner; David S Stephens
Journal:  Future Microbiol       Date:  2012-08       Impact factor: 3.165

Review 5.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

6.  Chlorhexidine Induces VanA-Type Vancomycin Resistance Genes in Enterococci.

Authors:  Pooja Bhardwaj; Elizabeth Ziegler; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Emergence and Transmission of Daptomycin and Vancomycin-Resistant Enterococci Between Patients and Hospital Rooms.

Authors:  Lynn El Haddad; Blake M Hanson; Cesar A Arias; Shashank S Ghantoji; Cynthia P Harb; Mark Stibich; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2021-12-16       Impact factor: 9.079

8.  Detection of vancomycin resistances in enterococci within 3 ½ hours.

Authors:  U-Ch Schröder; C Beleites; C Assmann; U Glaser; U Hübner; W Pfister; W Fritzsche; J Popp; U Neugebauer
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

9.  Developments in Glycopeptide Antibiotics.

Authors:  Mark A T Blaskovich; Karl A Hansford; Mark S Butler; ZhiGuang Jia; Alan E Mark; Matthew A Cooper
Journal:  ACS Infect Dis       Date:  2018-02-19       Impact factor: 5.084

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.

Authors:  Valentin Al Jalali; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.